Back
Single-allele chromatin interactions identify regulatory hubs in dynamic compartmentalized domains
Scientific Publications
December 2018
NATURE GENETICS
Oudelaar AM, Davies JOJ, Hanssen LLP, Telenius JM, Schwessinger R, Liu Y, Brown JM, Downes DJ, Chiariello AM, Bianco S, Nicodemi M, Buckle VJ, Dekker J, Higgs DR, Hughes JR. PMID: 30374068
More News from Nucleome
News
November 2024
High resolution genetic mapping has identified a novel disease target for rheumatoid arthritis
Despite clinicians having a variety of therapeutic options for rheumatoid arthritis (RA), very few p...
Read more
Scientific Publications
November 2024
Illuminating the Dark Genome to enable drug discovery from human genetics
The Dark Genome Symposium Heward J, Smith J, Owers L, Davidson B, James-Bott A, Repapi E, Hertweck A...
Read more
Scientific Publications
November 2024
High resolution genetic mapping has identified a novel disease target for rheumatoid arthritis
The Dark Genome Symposium Hargreaves C, Jozefowska W, Lucchesi D, Maio S, Hertweck A, Repapi E, Sutt...
Read more
News
October 2024
Nucleome Therapeutics announces a strategic collaboration with Johnson & Johnson to map genetic associations linked to autoimmune disease
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomi...
Read more
Video
September 2024
Biotech TV interview with CEO Mark Bodmer
New CEO Mark Bodmer describes the value in understanding the non-coding region of the genome and how...
Read more
News
July 2024
Nucleome Therapeutics appoints Mark Bodmer as Chief Executive Officer
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomi...
Read more
News
July 2024
Nucleome Therapeutics announces transition of leadership
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomi...
Read more
News
April 2024
Nucleome Therapeutics establishes Scientific Advisory Board of world-leading experts and appoints Dr John Davis as Non-Executive Director of the Board
Newly founded SAB comprised of experts across dark genome genetics and drug discovery. Dr John Davis...
Read more
News
November 2023
Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer
Key appointment bringing 30 years of drug discovery and development expertise as the Company continu...
Read more
News
November 2023
Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium
• Event brings together leading academics, industry representatives and investors to share progres...
Read more